Stay updated on Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial

Sign up to get notified when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the efficacy or safety data of Semaglutide once-weekly versus placebo as an add-on to SGLT-2 inhibitor therapy in subjects with Type 2 Diabetes Mellitus.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:14.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the need for informed consent and outlining both inclusion and exclusion criteria for participants. Previously, no information was provided in this section.
    Difference
    22%
    Check dated 2024-05-22T21:20:24.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T21:51:31.000Z thumbnail image

Stay in the know with updates to Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.